It is also reported that the AKT inhibitor AZD5363 potently inhibits proliferation and induces apoptosis in prostate cancer cell lines and has anticancer activity in vivo in androgen-sensitive and castration-resistant phases of the LNCaP xenograft model. The gene discussed is AKT1; the disease is prostate carcinoma.